-
Carl Icahn slams Illumina’s Q1 outcomes and cost-cutting plan
Carl Icahn speaks at Delivering Alpha in New York on September 13, 2016. David A Grogan | CNBC Carl Icahn called on Friday illuminas first-quarter results were “very disappointing” and slammed the DNA sequencing company’s new cost-cutting plans. The activist investor, which owns a 1.4% stake in Illumina, is in a heated proxy battle with…
-
Merck (MRK) Earnings Report Q1 2023
note on Thursday reported first-quarter sales and adjusted earnings that beat Wall Street expectations, despite a sharp drop in sales of its Covid antiviral treatment molnupiravir. Sales of molnupiravir collapsed to $392 million during the period, down 88% from the $3.2 billion reported for the first quarter of 2022. Merck said the decline was primarily…
-
Eli Lilly (LLY) Q1 Income 2023
Medical bottles and syringes with the logo of Eli Lilly and Company are seen on a screen in the background in this illustrative photo taken in Krakow, Poland, on November 10, 2022. Jakub Porzycki | Nurphoto | Getty Images Eli LilliFirst-quarter results missed expectations on Thursday, but the drug company raised its full-year guidance. Before…
-
Medicare will take over Alzheimer’s remedy Leqembi after FDA approval
Chiquita Brooks-LaSure testifies before the Senate Finance Committee during her nomination hearing for Administrator of the Centers for Medicare & Medicaid Services in Washington on Thursday, April 15, 2021. Caroline Brehmann | CQ Roll Call, Inc. | Getty Images Medicare will cover new Alzheimer’s treatment Leqembi for all patients eligible under the drug’s label when…
-
Illumina plans to chop prices because it faces shrinking margins
A building on the Illumina World Headquarters campus is shown on September 1, 2021 in San Diego, California. Mike Blake | Reuters Enlightenment on Tuesday unveiled cost-cutting plans to improve the DNA sequencing company’s shrinking margins. The plans aim to cut Illumina’s annualized spend by more than $100 million starting later this year, according to…
-
J&J broadcasts IPO costs for shopper spinoff Kenvue
Johnson & Johnson products for sale in New York. Scott Mill | CNBC Johnson&Johnson will price shares of its consumer-health spinoff Kenvue at $20 to $23 in an IPO later this year, the company said in a regulatory filing filed Monday. The spinoff, which would be valued at around $40 billion at this share range,…
-
Oxford launch of malaria vaccine might have ‘main’ impression on sub-Saharan Africa, says economist
Close-up of a yellow fever mosquito biting human skin. It is a Culicidae vector of malaria, yellow fever, chikungunya, dengue and Zika virus in Brazil locally known as Mosquito da Dengue. João Paulo Burini | moment | Getty Images Nigeria this week joined Ghana in tentatively approving a new malaria vaccine being developed by Oxford…
-
Senate invoice proposes insulin worth cap for diabetes sufferers
In this photo illustration, Novo Nordisk insulin pens are on display on March 14, 2023 in Miami, Florida. Joe Raedle | Getty Images A bipartisan Senate bill introduced this week would limit the price of insulin to $35 a month for people with private insurance. The bill, drafted by Sens. Jeanne Shaheen, DN.H., and Susan…
-
AI is on the coronary heart of HIMSS to scale back paperwork
Participants of the HIMSS conference walk around the exhibition area Source: HIMSS Debates about artificial intelligence and its role in healthcare were the focus of this week’s HIMSS Global Health Conference in Chicago, which brought together more than 35,000 physicians, other healthcare professionals, executives and engineers to discuss the latest advances in healthcare and technology.…
-
Drug firm CEOs to testify earlier than Senate Well being on insulin worth
Pictured here is a Novo Nordisk insulin pen on display on March 14, 2023 in Miami, Florida. Joe Raedle | News from Getty Images | Getty Images The top executives of the three drug companies that control 90% of the global insulin market will testify before the Senate Health Committee on May 10 about cutting…